<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04400864</url>
  </required_header>
  <id_info>
    <org_study_id>0122-19-rmc</org_study_id>
    <nct_id>NCT04400864</nct_id>
  </id_info>
  <brief_title>Mediterranean Diet Versus Paleolithic Diet for the Treatment of Non Alcohlic Fatty Liver Disease</brief_title>
  <acronym>PALMED</acronym>
  <official_title>Mediterranean Diet Versus Paleolithic Diet for the Treatment of Non Alcohlic Fatty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hebrew University of Jerusalem</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non- alcoholic fatty liver disease (NAFLD) is one of metabolic syndrome manifestation, and
      has become the leading cause for cirrhosis and the need for liver transplantation.

      The Mediterranean diet showed in many trials its benefit in the treatment of the metabolic
      syndrome and NAFLD. The Paleolithic Diet includes meat, fish, fruits, vegetables, nuts and
      seeds and avoidance of processed food and most of carbohydrates. In some studies this diet
      seemed to decrease triglycerides levels and improve insulin resistance.

      The aim of this study is to evaluate the influance of the paleolithic diat for the treatment
      of NAFLD, as shown in the Mediterranean Diet.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recruitment of 60 patients with the diagnosis NAFLD from clinics in Rabin Medical center,
      aged 18-65.

      Two study groups- Mediterranean Diet and Paleolithic Diet The dietitian will assign randomly
      for the study groups, and will assess diet adherence within 6 weeks of the trial and in its
      end- after 3 months.

      blood test for liver enzymes, lipids, crp, mda and HbA1C, will be taken at recruitment and
      after 3 months.

      Ultrasound and elastography will be tested at recruitment and after 3 months, to evaluate the
      degree of the fatty liver, by a the same doctor who is blind to the study groups.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 30, 2019</start_date>
  <completion_date type="Anticipated">May 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in the severity of the fatty liver measured by ultrasound and elastography.</measure>
    <time_frame>3 months</time_frame>
    <description>Changes in fatty liver severity score according to ultrasound wave intensity analysis- light ; moderate ; severe.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in HbA1C</measure>
    <time_frame>3 months</time_frame>
    <description>Blood tests for HbA1C are taken at the beginning and the end of the trial, and analyzed for changes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Triglycerides levels</measure>
    <time_frame>3 months</time_frame>
    <description>Blood tests for Triglycerides are taken at the beginning and the end of the trial, and analyzed for changes.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Non-Alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Mediterranean Diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nutritional guidelines based on the principals of the Mediterranean Diet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paleolithic Diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nutritional guidelines based on the principals of thePaleolithic Diet</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dietary intervention</intervention_name>
    <description>dietary counseling based on the principals pf the dietary intervention group.</description>
    <arm_group_label>Mediterranean Diet</arm_group_label>
    <arm_group_label>Paleolithic Diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  NAFLD

        Exclusion Criteria:

          -  pregnancy

          -  Chronic kidney disease

          -  post transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amir Shlomai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rabin Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amir Shlomai, MD</last_name>
    <phone>03-9376753</phone>
    <email>amirsh9@clalit.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hagit Lustigman, RD</last_name>
    <phone>039376034</phone>
    <email>hagitl2@clalait.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petah tikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amir Shlomai, MD</last_name>
      <phone>03-9376753</phone>
      <email>amirsh9@clalit.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Hagit Lustigman, RD</last_name>
      <phone>039376034</phone>
      <email>hagitl2@clalit.org.il</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 20, 2020</study_first_submitted>
  <study_first_submitted_qc>May 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 26, 2020</study_first_posted>
  <last_update_submitted>May 31, 2020</last_update_submitted>
  <last_update_submitted_qc>May 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rabin Medical Center</investigator_affiliation>
    <investigator_full_name>AMIR SHLOMAI</investigator_full_name>
    <investigator_title>Head of internal medicine department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

